Skip to navigation Skip to content

Chronic thromboembolic pulmonary hypertension (CTEPH) Program in Pharmaceutical Benefits Scheme (PBS) 012-18051110

Expand/Collapse all sectionsExpand all


This document outlines details of PBS-subsidised riociguat for patients with chronic thromboembolic pulmonary hypertension (CTEPH).

CTEPH and listing dates

CTEPH is a condition resulting in blood flow obstruction through the lungs.

Listing date: riociguat - 1 January 2017.

See Written Authority Required Drugs for more details.

Enquiries

Transfer enquiries about prescription arrangements to PBS Complex Drugs Programs, and choose the option relevant to the condition treated.

The Resources page contains:

  • application forms
  • contact details
  • item and restriction codes
  • the PBS schedule
  • Services Australia website link

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA System)

Process telephone Authority approval application

Processing and National Demand Allocation (PaNDA)

Processing Complex Authority Required Listings

Processing Written Authority requests

Written Authority Required Drugs